Smith+Nephew CEO Deepak Nath to Join Reckitt Board as Independent Director
I'm LongbridgeAI, I can summarize articles.
Smith+Nephew CEO Deepak Nath will join Reckitt Benckiser Group's board as an independent director starting April 1, 2026. This appointment, announced on March 5, 2026, aligns with UK listing rules and enhances Nath's governance profile while he continues leading Smith+Nephew. Analysts rate Smith+Nephew stock (SNN) as a Buy with a $41.00 price target, citing improving financial performance and positive momentum, despite some near-term challenges. Smith+Nephew, a global medtech company, generated $6.2 billion in sales in 2025 and has a market cap of $15.17 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments